S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
NASDAQ:ORGO

Organogenesis (ORGO) Stock Price, News & Analysis

$2.90
+0.04 (+1.40%)
(As of 04/19/2024 ET)
Today's Range
$2.81
$2.91
50-Day Range
$2.61
$3.84
52-Week Range
$1.79
$4.70
Volume
421,209 shs
Average Volume
913,366 shs
Market Capitalization
$382.68 million
P/E Ratio
72.52
Dividend Yield
N/A
Price Target
$4.83

Organogenesis MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
66.7% Upside
$4.83 Price Target
Short Interest
Healthy
9.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.01
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.02 out of 5 stars

Medical Sector

171st out of 909 stocks

Pharmaceutical Preparations Industry

64th out of 424 stocks

ORGO stock logo

About Organogenesis Stock (NASDAQ:ORGO)

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

ORGO Stock Price History

ORGO Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Organogenesis Holdings Inc. Cl A
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Recap: Organogenesis Hldgs Q4 Earnings
A Preview Of Organogenesis Hldgs's Earnings
Organogenesis Holdings Inc - Ordinary Shares - Class A
3 Biotech Stocks Flowing With Investment Potential
See More Headlines
Receive ORGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
4/21/2024
Next Earnings (Confirmed)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORGO
Fax
N/A
Employees
862
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.83
High Stock Price Target
$6.00
Low Stock Price Target
$3.50
Potential Upside/Downside
+66.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$4.95 million
Pretax Margin
2.40%

Debt

Sales & Book Value

Annual Sales
$433.14 million
Cash Flow
$0.21 per share
Book Value
$2.11 per share

Miscellaneous

Free Float
87,096,000
Market Cap
$382.68 million
Optionable
Optionable
Beta
1.57
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

ORGO Stock Analysis - Frequently Asked Questions

Should I buy or sell Organogenesis stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ORGO shares.
View ORGO analyst ratings
or view top-rated stocks.

What is Organogenesis' stock price target for 2024?

3 Wall Street research analysts have issued 12 month price targets for Organogenesis' stock. Their ORGO share price targets range from $3.50 to $6.00. On average, they expect the company's stock price to reach $4.83 in the next twelve months. This suggests a possible upside of 66.7% from the stock's current price.
View analysts price targets for ORGO
or view top-rated stocks among Wall Street analysts.

How have ORGO shares performed in 2024?

Organogenesis' stock was trading at $4.09 at the beginning of the year. Since then, ORGO shares have decreased by 29.1% and is now trading at $2.90.
View the best growth stocks for 2024 here
.

When is Organogenesis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ORGO earnings forecast
.

How can I listen to Organogenesis' earnings call?

Organogenesis will be holding an earnings conference call on Thursday, May 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc. (NASDAQ:ORGO) announced its earnings results on Tuesday, November, 9th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.03. The business had revenue of $113.75 million for the quarter, compared to analyst estimates of $112.10 million. Organogenesis had a net margin of 1.14% and a trailing twelve-month return on equity of 1.81%. During the same quarter in the prior year, the company earned $0.19 earnings per share.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $445.0 million-$470.0 million, compared to the consensus revenue estimate of $456.0 million.

What other stocks do shareholders of Organogenesis own?
Who are Organogenesis' major shareholders?

Organogenesis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.38%) and Denali Advisors LLC (0.03%). Insiders that own company stock include 2016 Organo 10-Year Grat U/ Gn, Albert Erani, Antonio S Montecalvo, Arthur S Leibowitz, Dennis Erani, Gary S Gillheeney, Gary S Gillheeney, Glenn H Nussdorf, Michael W Katz and Michael W Katz.
View institutional ownership trends
.

How do I buy shares of Organogenesis?

Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ORGO) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners